Skip to main content

Advertisement

Table 1 Patient characteristics

From: Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy

Characteristic No. of patients %
No. of enrolled 15 100.0%
Age, y   
  Median 56  
  Range 44-66  
Chemotherapy
  neoadjuvant 3 20.0%
  adjuvant 10 66.7%
  palliative 2 13.3%
tumor hormone receptor
  ER(+), PR(+) 5 33.3%
  ER(+), PR(-) 3 20.0%
  ER(-), PR(+) 1 6.7%
  ER(-), PR(-) 5 33.3%
  not applicable 1 6.7%
Her2/neu
  Absent 5 33.3%
  1+ 3 20.0%
  2+ 4 26.7%
  3+ 2 13.3%
  not applicable 1 6.7%
GCSF administration
  Yes 7 46.7%
  No 8 53.3%
pT stage*
  pT1 3 20.0%
  pT2 9 60.0%
  pT3 0 0.0%
  pT4 3 20.0%
pN stage*
  pN0 6 40.0%
  pN1 4 26.7%
  pN2 3 20.0%
  pN3 1 6.7%
  not applicable 1 6.7%
Tumor grade
  grade 1 2 13.3%
  grade 2 6 40.0%
  grade 3 6 40.0%
  not applicable 1 6.7%
Distant metastases
  Yes 2 13.3%
  No 13 86.7%
Chemotherapy regimen
  Anthracycline-based 7 46.7%
  Taxane-based 7 46.7%
  Others** 2 13.3%
  1. *pT, pN stage: according to definition of AJCC 7th edition staging system.
  2. **Others include: liposomal doxorubicin, vinorelbine. ER: estrogen receptor; PR: progesterone receptor; GCSF: Granulocyte colony-stimulating factor.